150 related articles for article (PubMed ID: 32598192)
1. Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Kim YJ; Oremus M; Chen HH; McFarlane T; Shah D; Horton S
Future Oncol; 2020 Sep; 16(27):2045-2058. PubMed ID: 32598192
[No Abstract] [Full Text] [Related]
2. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.
Juergens RA; Mariano C; Jolivet J; Finn N; Rothenstein J; Reaume MN; Faghih A; Labbé C; Owen S; Shepherd FA; Villeneuve J; Romeyer F; Pettersson F; Butts C
Curr Oncol; 2018 Dec; 25(6):384-392. PubMed ID: 30607113
[TBL] [Abstract][Full Text] [Related]
3. Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Geier M; Descourt R; Corre R; Léveiller G; Lamy R; Goarant É; Bizec JL; Bernier C; Quéré G; Amrane K; Gaye E; Lucia F; Burte E; Chouaid C; Robinet G
Cancer Med; 2020 Oct; 9(19):6923-6932. PubMed ID: 32412157
[TBL] [Abstract][Full Text] [Related]
4. Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.
Saka H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Horinouchi H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Yada N; Tamura T
Jpn J Clin Oncol; 2021 Jan; 51(1):106-113. PubMed ID: 33020837
[TBL] [Abstract][Full Text] [Related]
5. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
6. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A
PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185
[TBL] [Abstract][Full Text] [Related]
7. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice.
Merino Almazán M; Duarte Pérez JM; Marín Pozo JF; Ortega Granados AL; Muros De Fuentes B; Quesada Sanz P; Gago Sánchez AI; Rodríguez Gómez P; Jurado García JM; Artime Rodríguez-Hermida F; Martínez Bautista MJ; Rueda Ramos A; Mora Rodríguez B; Martínez Díaz MC; Nieto Guindo P; Garrido Siles M; Villatoro Roldán R; Roldán Morales JC; Artacho Criado SM; Baños Roldán Ú; Inoriza Rueda Á; Garrido Martínez MT
Int J Clin Pharm; 2019 Feb; 41(1):272-279. PubMed ID: 30578473
[TBL] [Abstract][Full Text] [Related]
8. Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.
Dudnik E; Moskovitz M; Agbarya A; Gottfried T; Shochat T; Urban D; Zer A; Rotem O; Moore A; Yust S; Peled N; Wollner M; Bar J;
Int J Cancer; 2021 Mar; 148(5):1183-1191. PubMed ID: 32875571
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
Juarez-Garcia A; Sharma R; Hunger M; Kayaniyil S; Penrod JR; Chouaïd C
Lung Cancer; 2022 Apr; 166():205-220. PubMed ID: 35316754
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
[TBL] [Abstract][Full Text] [Related]
11. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.
Veraldi M; Esposito S; Naturale MD; Oradei M; Cosco D; Francesco AE; Cicchetti A; Bidino RD
J Oncol Pharm Pract; 2021 Jun; 27(4):877-886. PubMed ID: 32686615
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy rechallenge in patients with non-small-cell lung cancer.
España S; Guasch I; Carcereny E
Pulmonology; 2020; 26(4):252-254. PubMed ID: 32354686
[No Abstract] [Full Text] [Related]
14. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey.
Hata H; Mio T; Yamashita D; Matsumura C; Chisaki Y; Motohashi H; Yano Y
Cancer Control; 2020; 27(4):1073274820977200. PubMed ID: 33297768
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
[TBL] [Abstract][Full Text] [Related]
16. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
17. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract][Full Text] [Related]
18. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Debieuvre D; Juergens RA; Asselain B; Audigier-Valette C; Auliac JB; Barlesi F; Benoit N; Bombaron P; Butts CA; Dixmier A; Gröschel A; Gutz S; Labbé C; Moro-Sibilot D; Pérol M; Raspaud C; Schumann C; Juarez-Garcia A; Lakhdari K; Pettersson F; Penrod JR; Reynaud D; Waldenberger D; Allan V; Sebastian M
Lung Cancer; 2021 Jul; 157():40-47. PubMed ID: 33980420
[TBL] [Abstract][Full Text] [Related]
19. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Pantano F; Russano M; Berruti A; Mansueto G; Migliorino MR; Adamo V; Aprile G; Gelibter A; Ficorella C; Falcone A; Russo A; Aieta M; Maio M; Martelli O; Barni S; Napolitano A; Roca E; Quadrini S; Iacono D; Russo A; Calvetti L; Occhipinti MA; Cortellini A; Vasile E; Passiglia F; Imperatori M; Calabrò L; Di Giacomo AM; Petrelli F; Pasquini G; Franchina T; Venditti O; Intagliata S; Galvano A; Fioroni I; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Mar; 20(3):319-326. PubMed ID: 32011207
[No Abstract] [Full Text] [Related]
20. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
